Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Haihe Biopharma's Haizexin (risovalisib mesylate) wins Japan approval for PIK3CA-mutated ovarian clear cell carcinoma following Ph2 data
Small molecule, cancer, PI3K inhibitor, ovarian cancer, PIK3CA mutation - Read more

Sanofi, Kali Therapeutics partner on autoimmune tri-specific antibody KT501, $180M upfront, $1.05B milestones
Licensing deal, autoimmune, antibody, milestone payments - Read more

BMS, insitro expand AI-powered ALS partnership with two new targets, triggering $10M milestone
Research collaboration, neurological, AI/ML, small molecule, milestone payments - Read more

Everest Medicines, Corxel Pharmaceuticals asset purchase agreement for CARDAMYST nasal spray, $30M upfront, $20M milestones
Asset purchase agreement, cardiovascular, nasal spray, milestone payments, commercialization - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Insmed's Arikayce hits Ph3 endpoints for Mycobacterium avium complex lung infection label expansion
Antibiotic, infectious disease, inhaled therapy, MAC lung infection, culture conversion - Read more

Apogee Therapeutics' zumilokibart (IL-13 inhibitor) meets Ph2 maintenance goals for atopic dermatitis treatment
Antibody, autoimmune, monoclonal antibody, atopic dermatitis, IL-13 target - Read more

Prestige Biopharma's HD204 (bevacizumab) biosimilar meets Ph3 endpoints for non-small cell lung cancer treatment
Antibody, cancer, biosimilar, non-small cell lung cancer, bevacizumab, VEGF inhibitor - Read more

Innovent Biologics' efdamrofusp alfa (IBI302) meets Ph3 primary endpoint for neovascular age-related macular degeneration in China
Protein therapy, ophthalmology, VEGFR fusion protein, neovascular age-related macular degeneration, extended-interval dosing - Read more

WuXi AppTec US revenue surges 34% to $4.5B, now comprises 72% of total sales
Contract research organization, strategic, financial, operational - Read more [Paywall]

Oryon Cell Therapies raises $42M Series A, Parkinson's cell therapy replacing dopaminergic neurons
Cell therapy, Parkinson's disease, neurological, autologous therapy - Read more

Laigo Bio raises €17M ($19.68M) seed round for precision membrane protein degraders
Protein degradation, oncology, autoimmune, antibody, preclinical - Read more

Congruence Therapeutics raises $39.5M funding, clinical-stage small molecule correctors platform
Clinical-stage, small molecule, platform technology, rare disease, neurological - Read more

Novartis commits $480M to expand manufacturing in Beijing and R&D operations in Shanghai, China
Manufacturing, strategic, major transaction, operational - Read more

Gilead Sciences to acquire Ouro Medicines for first-in-class T cell engager autoimmune disease program
T cell engager, autoimmune, strategic, major transaction - Read more

Insilico Medicine launches PandaClaw AI agent to accelerate drug discovery and target identification processes
AI drug discovery, multi-therapeutic, operational, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

EyePoint sues Ocular Therapeutix for alleged defamation campaign over competing retina drugs Duravyu and Axpaxli
Intravitreal insert, ophthalmology, competitive, operational - Read more

FDA schedules June hearing to gather public feedback on controversial national priority voucher program
Regulatory, operational, strategic, competitive - Read more

Pfizer and Valneva plan regulatory approval for LB6V Lyme disease vaccine despite mixed Ph3 results
Vaccine, infectious disease, Lyme disease, tick-borne disease - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here